FY2026 Earnings Estimate for EYPT Issued By Chardan Capital

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Research analysts at Chardan Capital issued their FY2026 EPS estimates for EyePoint Pharmaceuticals in a research note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings of ($2.82) per share for the year. Chardan Capital currently has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.02 million.

A number of other analysts also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. Finally, Citigroup started coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price for the company. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Stock Down 1.6 %

Shares of EyePoint Pharmaceuticals stock opened at $6.24 on Wednesday. The business has a fifty day simple moving average of $6.88 and a 200-day simple moving average of $8.28. EyePoint Pharmaceuticals has a fifty-two week low of $5.54 and a fifty-two week high of $23.65. The firm has a market cap of $428.87 million, a price-to-earnings ratio of -3.12 and a beta of 1.41.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System lifted its holdings in shares of EyePoint Pharmaceuticals by 3.8% during the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company’s stock valued at $362,000 after buying an additional 1,797 shares during the last quarter. Legal & General Group Plc raised its stake in shares of EyePoint Pharmaceuticals by 4.4% in the 4th quarter. Legal & General Group Plc now owns 46,263 shares of the company’s stock valued at $345,000 after acquiring an additional 1,932 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in EyePoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company’s stock worth $51,000 after purchasing an additional 1,940 shares during the last quarter. Invesco Ltd. boosted its position in EyePoint Pharmaceuticals by 16.1% during the fourth quarter. Invesco Ltd. now owns 15,657 shares of the company’s stock worth $117,000 after purchasing an additional 2,177 shares during the period. Finally, Teacher Retirement System of Texas grew its holdings in EyePoint Pharmaceuticals by 22.4% during the fourth quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company’s stock valued at $113,000 after purchasing an additional 2,782 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.